Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 16;18(5):1062.
doi: 10.3390/ijms18051062.

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Diego J Maselli  1   2 , Holly Keyt  3   4 , Marcos I Restrepo  5   6
Affiliations
Review

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Diego J Maselli et al. Int J Mol Sci. .

Abstract

The management of patients with chronic respiratory diseases affected by difficult to treat infections has become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that include Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species and non-tuberculous Mycobacteria (NTM). These challenges prompted scientists to deliver antimicrobial agents through the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. Subsequent research advances focused on the development of antibiotic agents able to achieve high tissue concentrations capable of reducing the bacterial load of difficult-to-treat organisms in hosts with chronic respiratory conditions. In this review, we focus on the evidence regarding the use of antibiotic therapies administered through the respiratory system via inhalation, nebulization or aerosolization, specifically in patients with chronic respiratory diseases that include CF, non-CF bronchiectasis and NTM. However, further research is required to address the potential benefits, mechanisms of action and applications of inhaled antibiotics for the management of difficult-to-treat infections in patients with chronic respiratory diseases.

Keywords: aerosols; bronchiectasis; cystic fibrosis; nontuberculous mycobacteria.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Mogayzel P.J., Jr., Naureckas E.T., Robinson K.A., Brady C., Guill M., Lahiri T., Lubsch L., Matsui J., Oermann C.M., Ratjen F., et al. Cystic Fibrosis Foundation pulmonary guideline. Pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann. Am. Thorac. Soc. 2014;11:1640–1650. doi: 10.1513/AnnalsATS.201404-166OC. - DOI - PubMed
    1. Mogayzel P.J., Jr., Naureckas E.T., Robinson K.A., Mueller G., Hadjiliadis D., Hoag J.B., Lubsch L., Hazle L., Sabadosa K., Marshall B. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 2013;187:680–689. doi: 10.1164/rccm.201207-1160OE. - DOI - PubMed
    1. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J. Cystic fibrosis pulmonary guidelines: Treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med. 2009;180:802–808. doi: 10.1164/rccm.200812-1845PP. - DOI - PubMed
    1. Pasteur M.C., Bilton D., Hill A.T. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65:577. doi: 10.1136/thx.2010.142778. - DOI - PubMed
    1. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., Holland S.M., Horsburgh R., Huitt G., Iademarco M.F., et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007;175:367–416. doi: 10.1164/rccm.200604-571ST. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources